Debonnel G Saint-André E Hebert C de Montigny C Lavoie N Blier P (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol10: 51–61.
2.
Gonzalez-Pinto A Gutiérrez M González N Elizagárate E Perez de Heredia JL Mico JA (2002) Efficacy and safety of venlafaxine–ECT combination in treatment-resistant depression. J Neuropsychiatry Clin Neurosci14: 206–209.
3.
Harrison CL Ferrier N Young AH (2004) Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol18: 200–204.
4.
Reis M Lundmark J Bjork H Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit24: 545–553.
5.
Ruiz-Doblado S (1997) Hacia una nueva generación de antidepresivos: Venlafaxina. Farmacoterapia14: 13–20.
6.
Shiloh R Nutt D Weizman A (1999) Atlas of Psychiatric Pharmacotherapy.London: Martin Dunitz, p. 24.
7.
Stahl SM (2002) Psicofarmacología esencial. Bases neurocientíficas y aplicaciones clínicas. Barcelona. Ariel268–274.
8.
Thase ME Sloan D (2006) Venlafaxina. In: AF Schatzberg CB Nemeroff (eds), Tratado de Psicofarmacología.Barcelona: Elsevier-Masson, pp. 379–391.
9.
Thase ME Shelton RC Khan A (2006) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard-and higher-dosing strategies. J Clin Psychopharmacol26: 250–258.
